We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-8.87%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.94B
AUM Growth
-$1.55B
Cap. Flow
-$1.01B
Cap. Flow %
-34.35%
Top 10 Hldgs %
43.7%
Holding
135
New
15
Increased
7
Reduced
68
Closed
31

Top Buys

Rank Stock Value
1
GLUE icon
Monte Rosa Therapeutics
GLUE
+$65.1M
2
BMEA icon
Biomea Fusion
BMEA
+$56M
3
JBIO
Jade Biosciences
JBIO
+$46.4M
4
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$46M
5
AMAM
Ambrx Biopharma Inc
AMAM
+$42.4M

Top Sells

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$76.5M
2
APLS
Apellis Pharmaceuticals
APLS
+$52.4M
3
NVAX icon
Novavax
NVAX
+$45.3M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$43.6M
5
OMER icon
Omeros
OMER
+$35.2M

Sector Composition

Rank Sector Weight
1 Healthcare 86.38%
2 Financials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RAIN
26
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$39.7M 1.35%
+2,626,660
New +$46M
ACRS icon
27
Aclaris Therapeutics
ACRS
$835M
$35.1M 1.19%
2,000,000
– –
CNTA
28
DELISTED
Centessa Pharmaceuticals
CNTA
$31.1M 1.05%
+1,427,273
New +$33.5M
MRTX
29
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$28.3M 0.96%
175,000
-100,000
-36% -$16.1M
YMAB
30
DELISTED
Y-mAbs Therapeutics
YMAB
$27M 0.92%
800,000
-430,000
-35% -$13.8M
AGEN
31
Agenus
AGEN
$346M
$26.4M 0.9%
244,945
-149,917
-38% -$11.2M
ELEV
32
DELISTED
Elevation Oncology
ELEV
$25.6M 0.87%
+1,983,165
New +$24.5M
VECT
33
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$25.5M 0.87%
+2,226,128
New +$33.8M
TWST icon
34
Twist Bioscience
TWST
$6.19B
$24.7M 0.84%
185,000
– –
RETA
35
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$23.8M 0.81%
168,150
-231,850
-58% -$26.2M
XLRN
36
DELISTED
Acceleron Pharma
XLRN
$22M 0.75%
175,000
-100,000
-36% -$12.6M
MASS icon
37
908 Devices
MASS
$347M
$21.1M 0.72%
545,320
-2
-0% -$91
BPMC
38
DELISTED
Blueprint Medicines
BPMC
$20.9M 0.71%
237,546
-9,654
-4% -$885K
LBPH
39
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$20.9M 0.71%
2,321,403
-34,597
-1% -$345K
IGMS
40
DELISTED
IGM Biosciences
IGMS
$20.8M 0.71%
250,000
-245,769
-50% -$18.2M
AXNX
41
DELISTED
Axonics, Inc. Common Stock
AXNX
$20.4M 0.69%
322,240
-370,760
-54% -$21.9M
PRAX icon
42
Praxis Precision Medicines
PRAX
$8.64B
$18.7M 0.64%
68,276
-3,334
-5% -$1.19M
DMTK
43
DELISTED
DermTech, Inc. Common Stock
DMTK
$18.7M 0.64%
450,000
-350,000
-44% -$14.4M
ALGS icon
44
Aligos Therapeutics
ALGS
$29.4M
$18.5M 0.63%
36,219
-14,468
-29% -$9.22M
OMER icon
45
Omeros
OMER
$937M
$17.8M 0.61%
1,200,000
-2,100,030
-64% -$35.2M
TRML
46
DELISTED
Tourmaline Bio
TRML
$17.3M 0.59%
+121,585
New +$18.6M
AKRO
47
DELISTED
Akero Therapeutics
AKRO
$14.9M 0.51%
600,000
-142,549
-19% -$4M
OMER icon
48
CALL
Omeros
OMER
$937M
$14.8M 0.5%
1,000,000
– –
PLRX icon
49
Pliant Therapeutics
PLRX
$65M
$14M 0.48%
482,413
-128,996
-21% -$4.02M
CABA icon
50
Cabaletta Bio
CABA
$452M
$13.9M 0.47%
1,611,623
-292,801
-15% -$2.88M
1
2
3 4 5

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q2 2021 Portfolio in Review

As of Q2 2021, Cormorant Asset Management held 135 positions worth $2.94B, down 34% from $4.49B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Cormorant Asset Management withdrew a net $1.01B in Q2 2021, closing 31 positions and reducing 68 holdings. Its most notable exit was Novavax, an estimated $45.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 75% a quarter earlier, followed by Financials.

Against the trend, Cormorant Asset Management opened a new position in Monte Rosa Therapeutics worth $69.5M.

  • Cormorant Asset Management's largest Q2 2021 buy was Monte Rosa Therapeutics: 3,193,973 shares worth $69.5M.
  • Cormorant Asset Management added most to Revolution Medicines in Q2 2021, an estimated $28.4M increase.
  • Cormorant Asset Management's biggest Q2 2021 reduction was C4 Therapeutics, cutting an estimated $76.5M.
  • Cormorant Asset Management fully exited Novavax in Q2 2021, selling an estimated $45.3M.
  • Cormorant Asset Management's ten largest holdings make up 44% of its $2.94B portfolio in Q2 2021.
  • Cormorant Asset Management opened 15 new positions and closed 31 in Q2 2021.
  • Cormorant Asset Management's portfolio value fell 34% quarter-over-quarter to $2.94B.

Based on Cormorant Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.